The first Oligonucleotides for CNS

Next week, our Chief Development Officer, Eva Chin, will be presenting at the first Oligonucleotides for CNS Summit occurring virtually next week from 22 to 24 February.

Eva’s presentation, ‘Developing Combination Therapies for SMA & ALS,’ will take place on Wednesday 24 February at 20:30 CET / 14:30 EST and will cover the benefit of combination therapies to improve health outcomes and quality of life in patients with spinal muscular atrophy and amyotrophic lateral sclerosis.